Skip to content
1 Minute Read

CRIO Welcomes Dr. Margaretta Nyilas to its Board of Directors

 BOSTON, MA – November 3, 2022CRIO, the industry’s leading eSource provider, announces the appointment of Dr. Margaretta Nyilas to its Board of Directors, effective immediately. 

Dr. Nyilas is a biopharmaceutical executive with over twenty years of diverse global industry experience, formerly at Otsuka Pharmaceuticals, Bristol Myers Squibb and Click Therapeutics. She has a proven track record of delivering high value assets such as ABILIFY MYCITE® (aripiprazole tablets with sensors), ABILIFY MAINTENA® (aripiprazole),  REXULTI™ (brexpiprazole), and ABILIFY® (aripiprazole). 

Currently, she is serving as a director and strategic advisor for the biopharmaceutical industry and as Venture Affiliate Partner with Boston Millennia Partners. 

Throughout her career, Dr. Nyilas has championed innovation in the clinical trial process and was an early adopter of electronic source data collection. She joins CRIO as its first independent director, bringing her unique blend of knowledge in clinical operations, technology and medicine.

“We couldn’t be happier with Margaretta joining the Board,” says Raymond Nomizu, JD, CEO and co-founder at CRIO. “With over 2,000 sites using our system across thousands of studies, we are leveraging our technology to create efficiencies for sites, sponsors and CROs. As an innovator in eClinical technology, Margaretta will provide invaluable insight and guidance to position our product roadmap and vision to the needs of clinical trial sponsors.”

Dr. Nyilas joins CRIO board members Sankesh Abbhi, formerly CEO of ArisGlobal; Tom Peterson, Venture Partner at Rally Ventures; and CEO, Raymond Nomizu. Ren Roome of Boston Millennia Partners serves as a board observer.

About CRIO

CRIO is an eClinical solution provider delivering innovative data capture technology for sites, sponsors and CROs. Innovation is at the heart of everything we do. As the industry’s leading eSource provider, CRIO’s unique architecture enables a single point of data capture that embeds quality and transparency at the point of entry, and creates significant downstream efficiencies. Finally. One system. One source. Today, CRIO supports more than 2,000 medical research sites and 4,000+ protocols worldwide. For more information about CRIO, visit clinicalresearch.io.

 

by Daenya McDonald Marketing Director
Share this post
You may also find interesting
Explore our Blog
Sitero x CRIO Blog
CRIO Company News
2 Minute Read -

CRIO & Sitero Partner to Drive Superior Enrollment, Speed, and Quality in Phase III Trial Using eSource

In the world of clinical trials, speed and quality are paramount. Every day a trial is delayed translates to postponed access to potentially life-saving treatments. Furthermore, compromised data quality can jeopardize the entire study, leading to wasted resources and potentially harmful outcomes for patients. Research sites are at the heart of this process, acting as...

CRIO x Trially
CRIO Company News
2 Minute Read -

CRIO-Trially Integration: Enhancing EMR Workflows and Patient Identification

CRIO-Trially Integration: Enhancing EMR Workflows and Patient Identification CRIO is making a significant impact in streamlining vendor relationships and improving site workflows through the launch of the Partners Program. As a CRIO-certified API partner, Trially can seamlessly integrate with CRIO’s recruitment module in addition to EMR systems, to analyze a site’s patient population and identify...

C6 Header
CRIO Company News
2 Minute Read -

Achieving Successful Patient Acquisition: How CRIO and C6’s Partnership Makes It Easy

In the dynamic field of clinical research, patient recruitment remains a persistent challenge. Well before a screening appointment, research sites spend enormous resources and time, talking to hundreds of prospects to find a few qualified candidates– a process that C6’s solutions aim to streamline.The collaboration between CRIO and C6, made possible by CRIO’s newly launched...

Get articles delivered to your inbox, every week